Suspended judgment. Treatment effect size in clinical trials: an example from surfactant trials

Affiliations

Meta-Analysis

T N Raju et al. Control Clin Trials. 1993 Dec.

. 1993 Dec;14(6):467-70.

doi: 10.1016/0197-2456(93)90027-b.

¹ Department of Pediatrics, School of Urban Planning and Policy, University of Illinois at Chicago 60612.

No abstract available

Similar articles

Surfactants in severe hyaline membrane disease.
[No authors listed] [No authors listed] Lancet. 1987 May 2;1(8540):1040-1. Lancet. 1987. PMID: 2883383 Clinical Trial. No abstract available.
[Study of treatment of hyaline membrane disease with pulmonary surfactant replacement in premature infant].
Ji SP, Zhang XL, Ma WX, Sun YP, Li XH, Yu JH. Ji SP, et al. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Apr;19(4):248. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007. PMID: 17448287 Clinical Trial. Chinese. No abstract available.
The effectiveness and cost of exogenous pulmonary surfactant replacement therapy.
Smith J, Pieper C, Gie RP. Smith J, et al. S Afr Med J. 1995 Nov;85(11):1192, 1195-6. S Afr Med J. 1995. PMID: 8597017 No abstract available.
Exogenous surfactant therapy in hyaline membrane disease.
Gitlin JD, Parad R, Taeusch HW Jr. Gitlin JD, et al. Semin Perinatol. 1984 Oct;8(4):272-82. Semin Perinatol. 1984. PMID: 6387924 Review.
A model of the effect of surfactant treatment on gas exchange in hyaline membrane disease.
Cotton RB. Cotton RB. Semin Perinatol. 1994 Feb;18(1):19-22. Semin Perinatol. 1994. PMID: 8209282 Review. No abstract available.